Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 684

Sort by

Sort Order Select

Journal Articles

Digestive complications in AML induction: Spotlight on neutropenic enterocolitis

Ornesta Bezhani, Raphaël Pichois, Magalie Joris, Lydia Montes, Hélène Kemp, Amandine Charbonnier, Sylvain Chantepie, Emilie Lemasle, Jean Pierre Marolleau, Delphine Lebon

Blood (2025) 146 (Supplement 1): 8201.

https://doi.org/10.1182/blood-2025-8201

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

Blood (2025) 146 (Supplement 1): 3883.

https://doi.org/10.1182/blood-2025-3883

Published: 2025

Journal Articles

Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML

Wissam Mahrez, Céline Berthon, Laurene Fenwarth, Carine Hauspie, Nicolas Duployez, Claude Preudhomme, Magalie Joris, Jean Pierre Marolleau, Delphine Lebon

Blood (2025) 146 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2025-3382

Published: 2025

Journal Articles

Non-genotoxic conditioning to increase donor chimerism levels in a mismatched murine transplant model for sickle cell disease

Mohamed Ali, Cynthia Joseph, Deanna Gaskin, Xin Xu, Djelika Kabore, Jean Pierre Mukendi, Ayotimofe Idowu, Mohamed Ahmed, Amelia Scheck, Agnieszka Czechowicz, Courtney Fitzhugh

Blood (2025) 146 (Supplement 1): 5858.

https://doi.org/10.1182/blood-2025-5858

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 368.

https://doi.org/10.1182/blood-2025-368

Published: 2025

Journal Articles

Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling

Xin Huang, Qingrong Huang, Ciril Abraham, Mimi Chen, Ying Wang, Yuanyuan Tian, Yongping Zhang, Gennaro Calendo, Jean-Pierre Issa, Yi Zhang

Blood (2025) 146 (Supplement 1): 5901.

https://doi.org/10.1182/blood-2025-5901

Published: 2025

Journal Articles

PIEZO1 activation controls erythropoiesis through calpain-dependent degradation of HSP70

Alexandre Willaume, Jessica Platon, Hakim Ouled-Haddou, Anaelle Lavillette, Emilie-Fleur Gautier, Virginie Salnot, Veronique Picard, Christilla Bachelot-Loza, Pascale Gaussem, Zoubida Karim, Jean Pierre Marolleau, Alexis Caulier, Loic Garcon

Blood (2025) 146 (Supplement 1): 609.

https://doi.org/10.1182/blood-2025-609

Published: 2025

Journal Articles

HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children

Blood (2025) 146 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2025-1582

Published: 2025

Journal Articles

Pharmacological inhibition of polrmt mimicking polrmt rare variants associated with sideroblastic anemia, strongly inhibits proliferation and differentiation of human erythroblasts

Ophélie Evrard, Cécile Deleschaux, Sophie Lefevre, Hakim Ouled-Haddou, Platon Jessica, Valérie Li Thiao Te, Catherine Paillard, Jean Pierre Marolleau, Mariano Ostuni, Kannengiesser Caroline, Loic Garcon

Blood (2025) 146 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2025-4658

Published: 2025

Journal Articles

Fusion-specific regulation of polyamine synthesis sensitizes to BCL-XL inhibition in TCF3::PBX1+ B-ALL

James Kim, Sarah Cherkaoui, Simona Ulrich, Bartimée Galvan, Chengkang Li, Caroline Mussak, Samanta Carbajal, Shannon Mezger, Beat Bornhauser, Raphael Morscher, Jean Pierre Bourquin

Blood (2025) 146 (Supplement 1): 3260.

https://doi.org/10.1182/blood-2025-3260

Published: 2025

Journal Articles

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Blood (2025) 146 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2025-1676

Published: 2025

Journal Articles

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

Anna Saorin, Anna Dehler, Bartimée Galvan, Fabio Steffen, Marine Ray, Dong Lu, Xin Yu, James Kim, Aneta Drakul, Samanta Kisele, Jin Wang, Jean-Pierre Bourquin, Beat C. Bornhauser

Blood (2025) 146 (7): 861–873.

https://doi.org/10.1182/blood.2025028938

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of the STOPAGO study

Blood (2025) 145 (2): 244–247.

https://doi.org/10.1182/blood.2024025707

Published: 2025

Includes: Supplemental data

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease

Mohamed Ali, Emily Limerick, Matthew Hsieh, Kalpana Upadhyaya, Xin Xu, Oswald Phang, Jean Pierre Kambala Mukendi, Katherine R. Calvo, Maria Lopez-Ocasio, Pradeep Dagur, Courtney Fitzhugh

Blood (2024) 144 (Supplement 1): 2167.

https://doi.org/10.1182/blood-2024-207487

Published: 2024

Journal Articles

Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Blood (2024) 144 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2024-208350

Published: 2024

Journal Articles

Ezh2 and Intracellular Ca2 + Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Ying WANG, Qingrong Huang, Ruqayyah sanders-Braggs, Yan Zhou, Robert Hooper, Yuanyuan Tian, Tatiana Kent, Richard Pomerantz, Gennaro Clando, Jean-Pierre Issa, Jonathan Soboloff, Yi Zhang

Blood (2024) 144 (Supplement 1): 4769.

https://doi.org/10.1182/blood-2024-212207

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Digestive complications in AML induction: Spotlight on neutropenic enterocolitis

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML

Non-genotoxic conditioning to increase donor chimerism levels in a mismatched murine transplant model for sickle cell disease

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling

PIEZO1 activation controls erythropoiesis through calpain-dependent degradation of HSP70

HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children

Pharmacological inhibition of polrmt mimicking polrmt rare variants associated with sideroblastic anemia, strongly inhibits proliferation and differentiation of human erythroblasts

Fusion-specific regulation of polyamine synthesis sensitizes to BCL-XL inhibition in TCF3::PBX1+ B-ALL

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

Long-term follow-up of the STOPAGO study

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease

Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Ezh2 and Intracellular Ca2 + Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only